Scroll Down


Lantern Pharma is a clinical stage oncology company that leverages Artificial Intelligence, Machine Learning, and genomics to develop targeted cancer therapies. Lantern develops therapies using genomic data, computational biology modeling, and Artificial Intelligence techniques to clarify the potential mechanism of action underlying drug-tumor response and to identify the patient groups most likely to respond to a therapy.

Today we are able to understand the genomic or biomarker basis of why certain patients respond exquisitely to certain therapies in cancer, while others fail to respond at all. At the same time, we are now able to access the computing power and algorithms required to make sense of the clinical and scientific data that is available to us, and then propose precision-focused trials that provide us with a compressed development timeline.

Emerging technologies are transforming the pace and insight of oncology drug development. We currently leverage:

• Artificial Intelligence
• Machine Learning
• Cloud Computing
• Automated genomic analysis
• Big data analytics

These techniques and methods have been robustly tested in many different industries. Applying technologies like machine learning in pharma and healthcare will help solve two of the central problems in cancer therapy:

1) Stratifying patients into responders and non-responders, ultimately de-risking and streamlining clinical trials.
2) Clarifying insight into the mechanism of action for drugs, resulting in improved molecular targeting.

Both of these problems have great potential to be improved through the application of A.I., which helps to shorten the drug development timeline and reduce costs for oncology pharmas.

We are continuously advancing our precision oncology therapeutics platform through partnerships with cloud computing firms, hospitals, clinical healthcare centers, investigator consortia, and tissue and data banks.



We’re transforming the lives of cancer patients by leveraging Artificial Intelligence and Machine Learning in order to stratify patients into responders and non-responders and more deeply understand how to personalize and develop targeted cancer therapies. This, in turn, significantly reduces the timeline and cost of treatment.

We’re developing breakthrough approaches that can potentially change the cost curve and risk involved in cancer therapy development. Our mission is to help patients with cancer lead better, longer lives.

A new approach to drug development

Partner with us

Our breakthrough approach requires an immense network of talented collaborators and partners. At Lantern Pharma we are constantly looking to align ourselves with like-minded companies, organizations and people to further our development of cancer therapies and pharmaceuticals.

We partner with academic institutions, companies and non-profits with:

  • Large genomic cancer data sets
  • Novel cancer cell lines, organoid and PDX models
  • Access to patient tumor samples
  • Innovative and big data approaches to solve complex problems
Partner with Us
“We are in the golden age of A.I. in medicine.”
Panna Sharma
Lantern Pharma
Success rate of cancer drugs in clinical trial testing
Cancer is the second leading cause of death after heart disease
$200 Billion
Current global oncology drug market
Biomarker-based trials are 12 times more likely to succeed